Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christina Zachar

Psychiatry Jackson, MI Medical Doctor

NPI 1265534804 CMS profile 239150

2301 E Michigan Ave, Jackson, MI 49202

Open in the dashboard

General payments

$4,215

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Zachar of Jackson, MI is reported in the CMS Open Payments database as having received $4,215 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $793 42
2024 General $864 35
2023 General $858 38
2022 General $829 47
2021 General $396 20
2020 General $109 1
2019 General $365 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Zachar
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Christina Zachar were reported at $793. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Christina Zachar Psychiatry median Middle half National median
2019 $365 $184 $59–$605 $163
2020 $109 $119 $36–$372 $114
2021 $396 $143 $43–$576 $132
2022 $829 $153 $50–$590 $149
2023 $858 $170 $56–$651 $160
2024 $864 $179 $57–$673 $164
2025 $793 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $712 40 payments
  2. AbbVie, Inc. $512 25 payments
  3. Alkermes, Inc. $478 20 payments
  4. Vanda Pharmaceuticals Inc. $457 21 payments
  5. Teva Pharmaceuticals USA, Inc. $450 17 payments
  6. ITI, Inc. $412 19 payments
  7. Janssen Pharmaceuticals, Inc $379 19 payments
  8. E.R. Squibb & Sons, L.L.C. $299 11 payments
  9. Neurocrine Biosciences, Inc. $216 9 payments
  10. Lundbeck LLC $159 9 payments
  11. Other $142 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,992 183 payments
  2. Education $223 13 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $478 20 payments
  2. ARISTADA Cns $478 20 payments
  3. ARISTADA Cns $478 20 payments
  4. ARISTADA Cns $478 20 payments
  5. FANAPT $457 21 payments
  6. VRAYLAR $440 21 payments
  7. REXULTI $424 16 payments
  8. ABILIFY MAINTENA $398 29 payments
  9. INVEGA SUSTENNA $364 18 payments
  10. LYBALVI $350 13 payments
  11. Other $2,484 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

5,359

Median for Psychiatry: 574

Drug cost

$1,101,414

Median for Psychiatry: $27,624

Branded share of claims

30.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Xr Deutetrabenazine Brand 18 $240,818
Invega Sustenna Paliperidone Palmitate Brand 71 $192,326
Abilify Maintena Aripiprazole Brand 41 $109,339
Vraylar Cariprazine Hcl Brand 91 $104,707
Clozapine Odt Clozapine Brand 173 $96,631
Rexulti Brexpiprazole Brand 33 $41,484
Fanapt Iloperidone Brand 14 $37,836
Nuedexta Dextromethorphan Hbr/Quinidine Brand 17 $27,427
Paliperidone Er Paliperidone Brand 191 $27,181
Trintellix Vortioxetine Hydrobromide Brand 36 $22,957

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$13,184

Medicare's payments for the services billed

Medicare patients

30

Average age 54

Services billed

237

16 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Diabetes 37%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $177
$177 91 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $137
$137 — —
ARISTADA
  • Alkermes, Inc. $105
$105 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $88
$88 71 —
CAPLYTA
  • ITI, Inc. $75
$75 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record